From palliative therapy to prolongation of survival: 223RaCl2 in the treatment of bone metastases
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
From palliative therapy to prolongation of survival: 223RaCl2 in the treatment of bone metastases
Authors
Keywords
-
Journal
Therapeutic Advances in Medical Oncology
Volume 8, Issue 4, Pages 294-304
Publisher
SAGE Publications
Online
2016-04-26
DOI
10.1177/1758834016640494
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Radium-223 chloride, a first-in-class alpha-pharmaceutical with a benign safety profile for patients with castration-resistant prostate cancer (CRPC) and bone metastases: Combined analysis of phase I and II clinical trials.
- (2017) S. Nilsson et al. JOURNAL OF CLINICAL ONCOLOGY
- Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting 223Ra-dichloride
- (2015) Massimiliano Pacilio et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- A Phase 1, Open-Label Study of the Biodistribution, Pharmacokinetics, and Dosimetry of 223Ra-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal Metastases
- (2015) S. J. Chittenden et al. JOURNAL OF NUCLEAR MEDICINE
- Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events
- (2014) M. R. Smith et al. ANNALS OF ONCOLOGY
- Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial
- (2014) Peter Hoskin et al. LANCET ONCOLOGY
- Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial
- (2014) Oliver Sartor et al. LANCET ONCOLOGY
- Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer
- (2013) Jorge A. Carrasquillo et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Two-Year Survival Follow-Up of the Randomized, Double-Blind, Placebo-Controlled Phase II Study of Radium-223 Chloride in Patients With Castration-Resistant Prostate Cancer and Bone Metastases
- (2012) Sten Nilsson et al. Clinical Genitourinary Cancer
- A randomized, dose–response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer
- (2012) S. Nilsson et al. EUROPEAN JOURNAL OF CANCER
- Dosimetry of 223Ra-chloride: dose to normal organs and tissues
- (2012) Michael Lassmann et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- A Randomized, Double-Blind, Dose-Finding, Multicenter, Phase 2 Study of Radium Chloride (Ra 223) in Patients with Bone Metastases and Castration-Resistant Prostate Cancer
- (2012) Christopher C. Parker et al. EUROPEAN UROLOGY
- A bone marrow toxicity model for223Ra alpha-emitter radiopharmaceutical therapy
- (2012) Robert F Hobbs et al. PHYSICS IN MEDICINE AND BIOLOGY
- Palliation and Survival After Repeated 188Re-HEDP Therapy of Hormone-Refractory Bone Metastases of Prostate Cancer: A Retrospective Analysis
- (2011) H.-J. Biersack et al. JOURNAL OF NUCLEAR MEDICINE
- Internal radiotherapy of painful bone metastases
- (2011) K. Liepe et al. METHODS
- Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: The effect of a bisphosphonate
- (2010) Clemens W.G.M. Löwik et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Incidence of Malignant Diseases in Humans Injected with Radium-224
- (2010) Elke Anna Nekolla et al. RADIATION RESEARCH
- Systemic Metabolic Radiopharmaceutical Therapy in the Treatment of Metastatic Bone Pain
- (2010) Fabio M. Paes et al. SEMINARS IN NUCLEAR MEDICINE
- Phase II Trial of Consolidation Docetaxel and Samarium-153 in Patients With Bone Metastases From Castration-Resistant Prostate Cancer
- (2009) Karim Fizazi et al. JOURNAL OF CLINICAL ONCOLOGY
- Increased risk of myeloid leukaemia in patients with ankylosing spondylitis following treatment with radium-224
- (2008) R. R. Wick et al. RHEUMATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now